Cost-effectiveness of immediate compared with delayed postpartum etonogestrel implant insertion

Obstetrics and Gynecology

Volumn 126, Issue 1, 2015, Pages 47-55

  Gariepy, Aileen M ^a   Duffy, Jennifer Y ^b   Xu, Xiao ^b  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ETONOGESTREL; CONTRACEPTIVE AGENT; DESOGESTREL;

ABORTION; ADULT; ARTICLE; CLINICAL DECISION MAKING; COHORT ANALYSIS; CONTRACEPTION; CONTRACEPTIVE BEHAVIOR; CONTROLLED STUDY; COST CONTROL; COST EFFECTIVENESS ANALYSIS; ECTOPIC PREGNANCY; ETONOGESTREL IMPLANT; EVALUATION STUDY; FEMALE; FOLLOW UP; HEALTH CARE COST; HUMAN; INTRAUTERINE CONTRACEPTIVE DEVICE; MAJOR CLINICAL STUDY; MEDICAID; PREGNANCY RATE; PRIORITY JOURNAL; PUERPERIUM; REIMBURSEMENT; SENSITIVITY ANALYSIS; SPONTANEOUS ABORTION; UNPLANNED PREGNANCY; ADOLESCENT; COMPARATIVE STUDY; COST BENEFIT ANALYSIS; DECISION SUPPORT SYSTEM; ECONOMICS; INFUSION PUMP; PREGNANCY; STATISTICAL MODEL; STATISTICS AND NUMERICAL DATA; UNITED STATES; YOUNG ADULT;

ADOLESCENT; ADULT; CONTRACEPTIVE AGENTS, FEMALE; COST-BENEFIT ANALYSIS; DECISION SUPPORT TECHNIQUES; DESOGESTREL; FEMALE; HEALTH CARE COSTS; HUMANS; INFUSION PUMPS, IMPLANTABLE; MODELS, ECONOMIC; POSTPARTUM PERIOD; PREGNANCY; PREGNANCY, UNPLANNED; UNITED STATES; YOUNG ADULT;

EID: 84932135103     PISSN: 00297844     EISSN: 1873233X     Source Type: Journal    
DOI: 10.1097/AOG.0000000000000907     Document Type: Article

References (49)

1. Finer LB, Zolna MR. Shifts in intended and unintended pregnancies in the United States, 2001-2008. Am J Public Health 2014;104(suppl 1):S43-8.
2. Sonfield A, Kost K, Gold RB, Finer LB. The public costs of births resulting from unintended pregnancies: national and state-level estimates. Perspect Sex Reprod Health 2011;43: 94-102.
3. Aiken AR, Creinin MD, Kaunitz AM, Nelson AL, Trussell J. Global fee prohibits postpartum provision of the most effective reversible contraceptives. Contraception 2014;90: 466-7.
4. Speroff L, Mishell DR Jr. The postpartum visit: it's time for a change in order to optimally initiate contraception. Contraception 2008;78:90-8.
5. Centers for Disease Control and Prevention (CDC). Medical Eligibility Criteria for Contraceptive Use, 2010. MMWR Recomm Rep 2010;59:1-86.
6. Brito MB, Ferriani RA, Quintana SM, Yazlle ME, Silva de Sá MF, Vieira CS. Safety of the etonogestrel-releasing implant during the immediate postpartum period: a pilot study. Contraception 2009;80:519-26.
7. Lewis LN, Doherty DA, Hickey M, Skinner SR. Implanon as a contraceptive choice for teenage mothers: a comparison of contraceptive choices, acceptability and repeat pregnancy. Contraception 2010;81:421-6.
8. Winner B, Peipert JF, Zhao Q, Buckel C, Madden T, Allsworth JE, et al. Effectiveness of long-acting reversible contraception. N Engl J Med 2012;366:1998-2007.
9. Eisenberg D, McNicholas C, Peipert JF. Cost as a barrier to long-acting reversible contraceptive (LARC) use in adolescents. J Adolesc Health 2013;52(suppl):S59-63.
10. Ogburn JA, Espey E, Stonehocker J. Barriers to intrauterine device insertion in postpartum women. Contraception 2005; 72:426-9.
11. Washington CI, Jamshidi R, Thung SF, Nayeri UA, Caughey AB, Werner EF. Timing of postpartum intrauterine device placement: a cost-effectiveness analysis. Fertil Steril 2015;103:131-7.
12. Jackson E, Glasier A. Return of ovulation and menses in postpartum nonlactating women: a systematic review. Obstet Gynecol 2011;117:657-62.
13. Reeves MF, Smith KJ, Creinin MD. Contraceptive effectiveness of immediate compared with delayed insertion of intrauterine devices after abortion: a decision analysis. Obstet Gynecol 2007;109:1286-94.
14. Daniels K, Daugherty J, Jones J. Current contraceptive status among women aged 15-44: United States, 2011-2013. NCHS data brief, no. 173. Hyattsville (MD): National Center for Health Statistics; 2014.
15. CDC national immunization surveys 2011 and 2012, provisional data, 2010 births. Available at: http://www.cdc. gov/breastfeeding/data/NIS-data/index. htm. Retrieved March 25, 2015.
16. Chiou CF, Trussell J, Reyes E, Knight K, Wallace J, Udani J, et al. Economic analysis of contraceptives for women. Contraception 2003;68:3-10.
17. Trussell J, Koenig J, Ellertson C, Stewart F. Preventing unintended pregnancy: the cost-effectiveness of three methods of emergency contraception. Am J Public Health 1997;87: 932-7.
18. Trussell J. The cost of unintended pregnancy in the United States. Contraception 2007;75:168-70.
19. Trussell J, Lalla AM, Doan QV, Reyes E, Pinto L, Gricar J. Cost effectiveness of contraceptives in the United States. Contraception 2009;79:5-14.
20. Hatcher R, Trussell J, Nelson A, Cates W, Stewart F, Kowal D. Contraceptive technology. 19th rev ed. New York (NY): Ardent Media; 2007.
21. Trussell J, Henry N, Hassan F, Prezioso A, Law A, Filonenko A. Burden of unintended pregnancy in the United States: potential savings with increased use of long-acting reversible contraception. Contraception 2013; 87:154-61.
22. Ventura SJ, Curtin SC, Abma JC, Henshaw SK. Estimated pregnancy rates and rates of pregnancy outcomes for the United States, 1990-2008. Natl Vital Stat Rep 2012;60:1-21.
23. Trussell J. Update on and correction to the cost-effectiveness of contraceptives in the United States. Contraception 2012; 85:611.
24. Centers for Medicare and Medicaid Services. Available at: http://www.cms. gov/Medicare/Medicare-Fee-for-Service-Payment/PhysicianFeeSched/PFS-Relative-Value-Files. html. Retrieved March 25, 2015.
25. Red book 2010 (red book drug topics). Montvale (NJ): PDR Network; 2010.
26. Hall KS, Trussell J. Types of combined oral contraceptives used by US women. Contraception 2012;86:659-65.
27. Kaiser Family Foundation. The role of Medicaid and Medicare in women's health care. JAMA 2013;309:1984.
28. Bureau of Labor Statistics. Consumer price index. Washington, DC: United States Deparmtent of Labor; 2012.
29. Xu X, Ivy JS, Patel DA, Patel SN, Smith DG, Ransom SB, et al. Pelvic floor consequences of cesarean delivery on maternal request in women with a single birth: a cost-effectiveness analysis. J Womens Health (Larchmt) 2010;19:147-60.
30. Wilson S, Tennant C, Sammel MD, Schreiber C. Immediate postpartum etonogestrel implant: a contraception option with long-term continuation. Contraception 2014;90:259-64.
31. Long-acting reversible contraception: implants and intrauterine devices. Practice Bulletin No. 121. American College of Obstetricians and Gynecologists. Obstet Gynecol 2011;118:184-96.
32. Gariepy AM, Simon EJ, Patel DA, Creinin MD, Schwarz EB. The impact of out-of-pocket expense on IUD utilization among women with private insurance. Contraception 2011; 84:e39-42.
33. Gurtcheff SE, Turok DK, Stoddard G, Murphy PA, Gibson M, Jones KP. Lactogenesis after early postpartum use of the contraceptive implant: a randomized controlled trial. Obstet Gynecol 2011;117:1114-21.
34. Phemister DA, Laurent S, Harrison FN Jr. Use of Norplant contraceptive implants in the immediate postpartum period: safety and tolerance. Am J Obstet Gynecol 1995;172:175-9.
35. Zhu BP, Rolfs RT, Nangle BE, Horan JM. Effect of the interval between pregnancies on perinatal outcomes. N Engl J Med 1999;340:589-94.
36. Zhu BP. Effect of interpregnancy interval on birth outcomes: findings from three recent US studies. Int J Gynaecol Obstet 2005;89(suppl 1):S25-33.
37. Levi E, Cantillo E, Ades V, Banks E, Murthy A. Immediate postplacental IUD insertion at cesarean delivery: a prospective cohort study. Contraception 2012;86:102-5.
38. Centers for Disease Control and Prevention (CDC). Postpartum care visits-11 states and New York City, 2004. MMWR Morb Mortal Wkly Rep 2007;56:1312-6.
39. Ghilarducci E, McCool W. The influence of postpartum home visits on clinic attendance. J Nurse Midwifery 1993;38:152-8.
40. Kogan MD, Leary M, Schaetzel TP. Factors associated with postpartum care among Massachusetts users of the maternal and infant care program. Fam Plann Perspect 1990;22: 128-30.
41. Landon BE, Schneider EC, Normand SL, Scholle SH, Pawlson LG, Epstein AM. Quality of care in Medicaid managed care and commercial health plans. JAMA 2007;298: 1674-81.
42. Stevens-Simon C, O'Connor P, Bassford K. Incentives enhance postpartum compliance among adolescent prenatal patients. J Adolesc Health 1994;15:396-9.
43. Weir S, Posner HE, Zhang J, Willis G, Baxter JD, Clark RE. Predictors of prenatal and postpartum care adequacy in a medicaid managed care population. Womens Health Issues 2011; 21:277-85.
44. Tocce K, Sheeder J, Python J, Teal SB. Long acting reversible contraception in postpartum adolescents: early initiation of etonogestrel implant is superior to IUDs in the outpatient setting. J Pediatr Adolesc Gynecol 2012;25:59-63.
45. Funk S, Miller MM, Mishell DR Jr, Archer DF, Poindexter A, Schmidt J, et al. Safety and efficacy of Implanon, a single-rod implantable contraceptive containing etonogestrel. Contraception 2005;71:319-26.
46. Croxatto HB, Urbancsek J, Massai R, Coelingh Bennink H, van Beek A. A multicentre efficacy and safety study of the single contraceptive implant Implanon. Implanon Study Group. Hum Reprod 1999;14:976-81.
47. Lakha F, Glasier AF. Continuation rates of Implanon in the UK: data from an observational study in a clinical setting. Contraception 2006;74:287-9.
48. Power J, French R, Cowan F. Subdermal implantable contraceptives versus other forms of reversible contraceptives or other implants as effective methods of preventing pregnancy. The Cochrane Database of Systematic Reviews 2007, Issue 3. Art. No.: CD001326. DOI: 10. 1002/14651858. CD001326. pub2.
49. Lipetz C, Phillips CJ, Fleming CF. The cost-effectiveness of a longacting reversible contraceptive (Implanon) relative to oral contraception in a community setting. Contraception 2009;79:304-9.